Breakthrough smart implant design to treat heart failure receives CE mark approval

The world’s first wireless cardiac pacing system for heart failure has achieved European CE mark approval. The WiSE™ (wireless stimulation endocardially) technology has been developed by EBR Systems, in collaboration with product design and development firm Cambridge Consultants. The groundbreaking technology could benefit 1.5 million heart failure patients worldwide.

WiSE is the only wireless endocardial pacing system for cardiac resynchronisation therapy (CRT) – a treatment for heart failure that uses an implantable pacemaker to improve the heart’s pumping efficiency by synchronising the left and right ventricles. Studies have demonstrated that successful CRT reduces heart failure symptoms, hospitalisation and mortality.

Conventional CRT devices use wires to deliver pacing pulses to the left ventricle. But these wires can break or otherwise fail – leading to complications in roughly 5-10% of cases. In addition, about 30% of patients do not respond to conventional CRT. Data suggests this is largely due to limitations on where current, approved leads can be placed in the heart’s venous anatomy to stimulate the left ventricle. It means more than $1 billion out of the $3.5 billion spent annually on CRT devices provides no patient benefit.

The WiSE system consists of a tiny electrode implanted in the left ventricle. With every heartbeat, it receives a synchronised ultrasound signal from a small transmitter placed between two ribs. The sounds waves are converted to electrical energy, providing cardiac pacing. The technology eliminates the need for a left ventricular lead and is designed to let the doctor place the stimulation point at an optimal, patient-specific location inside the left ventricle – which could potentially be more effective.

Cambridge Consultants used its expertise in integrated circuit design and signal processing to create two state-of-the-art, mixed-signal, application-specific integrated circuits (ASICs) – managed by its powerful XAP4 processor – to form the core of the WiSE system. The circuits interface with the ultrasonic transducers and heart-monitoring sensors.

“Power consumption, size and safety are critical when it comes to pacemaker technology so we faced a complex challenge,” said Simon Karger, head of surgical and interventional products at Cambridge Consultants. “During the development we created a full system hardware emulator of the final ASICs so that the other system elements and the software could be designed and fully tested more than a year before prototype ASICs were available. This approach dramatically reduced the overall time of the development.”

In a US trial earlier this year involving 35 patients who had failed to respond to conventional CRT, 97% were implanted successfully with the WiSE technology. Preliminary results indicate that 26 of the patients have successfully passed the six-month mark, with 81% improving their clinical composite score – a measure of symptom improvement. The remaining nine patients have not yet reached the six-month follow-up stage.

The CE mark approval means EBR Systems can now train European Union (EU) doctors to use the WiSE system – enabling more patients to benefit from the innovative therapy. The mark is awarded when a product complies with all relevant EU legislation – for example, health and safety requirements. EBR plans to work with leading European clinicians over the next 12 months to assess different strategies for optimising endocardial pacing locations that maximise CRT benefits.

“A growing body of evidence strongly suggests EBR’s WiSE technology can benefit patients who have failed to respond to conventional cardiac resychronisation implants,” said Allan Will, CEO of EBR Systems. “This unique technology represents a huge breakthrough in cardiac pacing therapy – which was why we chose to work with the world-class smart implant design skills of Cambridge Consultants to make it a reality in record time.”

Notes to editors

Cambridge Consultants develops breakthrough products, creates and licenses intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 50 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of more than 850 staff, including engineers, scientists, mathematicians and designers, in offices in Cambridge (UK), Boston (USA), Tokyo and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, digital health, energy and wireless communications. For more information, visit: www.cambridgeconsultants.com

Cambridge Consultants is part of Altran. Altran ranks as the undisputed global leader in Engineering and R&D services (ER&D). The company offers clients an unmatched value proposition to address their transformation and innovation needs. Altran works alongside its clients, from initial concept through industrialization, to invent the products and services of tomorrow. For over 35 years, the company has provided expertise in Automotive, Aeronautics, Space, Defense & Naval, Rail, Infra & Transport, Energy, Industrial & Consumer, Life Sciences, Communications, Semiconductor & Electronics, Software & Internet, Finance & Public Sector. The Aricent acquisition extends this leadership to semiconductor, digital experience and design innovation. Altran generated revenues of €2.9 billion in 2018, with some 47,000 employees in more than 30 countries.

Media downloads

pr-pr15-030_image1_v0.7.jpg, 0.5MB
pr-pr15-030_image2_v0.7.jpg, 1.2MB
pr-pr15-030_image3_v0.7.jpg, 1.2MB

PRESS CONTACTS

Cambridge Consultants

Richard
Leyland
Public Relations Manager
Cambridge Consultants

European agency

Josh
Salisbury